Last updated Nov 15, 2026
A newborn has frequent seizures starting on day 2 of life. Seizures are brief tonic events. By 3 months, seizures have resolved. Development is normal at follow-up.
AD (encephalopathy variants arise de novo); KCNQ2 (Kv7.2, a voltage-gated potassium channel subunit); severity tracks how much channel current a variant removes
Four subunits, often Kv7.2 with Kv7.3 (KCNQ3), form a pore that lets potassium leave the neuron. This outflow, the M-current, damps repetitive firing. Reduced current in excitatory neurons raises excitability and lowers seizure threshold, and the size of the loss predicts severity:
- Self-limited familial neonatal epilepsy (formerly benign familial neonatal epilepsy): truncating variants, whole-gene deletions, and mild missense variants cause haploinsufficiency, a modest loss of current (about 20% to 50% in cell studies). Penetrance is 77% to 85%. A variant predicted to cause haploinsufficiency nearly always means this self-limited form.
- KCNQ2 encephalopathy (neonatal-onset developmental and epileptic encephalopathy): de novo missense variants or in-frame indels clustered in the voltage sensor, the pore, and two C-terminal regions. One altered subunit can poison the whole four-subunit channel, a dominant-negative loss of more than 50% of current. Penetrance is complete.
- Gain of function: rare variants such as p.Arg201Cys increase current and cause developmental impairment without neonatal seizures, for example neonatal encephalopathy with non-epileptic myoclonus.
Mosaic parents of children with encephalopathy have had normal development, which suggests a severe variant must be present in enough cells to cause lasting disease.
- Benign familial neonatal epilepsy (BFNE): self-limited, normal development
- KCNQ2 encephalopathy: neonatal seizures, developmental impairment
- Molecular testing of KCNQ2 (epilepsy gene panel or exome) in neonatal-onset seizures, after excluding metabolic and structural causes
- The same panel covers the other early-onset developmental and epileptic encephalopathies, such as CDKL5 deficiency disorder, whose seizures usually begin in the first two months and which affects girls about four times as often as boys
- EEG and brain MRI characterize seizures and exclude acquired causes; the encephalopathic form often shows a burst-suppression or multifocal EEG
- Variant type guides phenotype: loss-of-function variants tend toward benign familial neonatal epilepsy, while certain missense (often gain-of-function) variants cause the encephalopathy
- Parental testing distinguishes inherited (benign familial) from de novo (often encephalopathy) variants; cascade testing and reproductive counseling once a variant is found (autosomal dominant)
- Sodium-channel blockers (carbamazepine, oxcarbazepine, phenytoin) are often effective, including in KCNQ2 encephalopathy
- Benign familial neonatal epilepsy is self-limited; seizures usually resolve within months and medication can often be weaned
- KCNQ2 encephalopathy needs developmental surveillance and early intervention for the associated impairment
- Counsel families on prognosis, which differs markedly between the benign and encephalopathic forms
"KCNQ2 seizures Quit by age 2": In the benign form (BFNE), neonatal seizures typically self-resolve within the first few months of life and respond well to medications (vs Dravet syndrome, which is drug-resistant).